NAFLD-Patient Guidelines: Why Are They Needed and Why Did It Take So Long to Have Them? - Sven Francque, MD, PhD

Innovations in NAFLD Care Webinar 2022

Why Endocrinologists Do Not Screen for NAFLD as a Complication of Type-2 Diabetes - Kenneth Cusi, MD, FACP, FACE

Innovations in NAFLD Care Webinar 2022

Immune Non-Responders and How Best to Define and Treat Them - Ricardo Diaz, MD

Goiânia HIV Clinical Forum 2021

Switching Therapy: Why, When and How? (Without Resistance Testing) -- Nickolas Paton

Chinese HIV Clinical Forum Educational Series 2021

How Will Technology Evolve Delivery Methods and Formulations - Eric Andrew Appel, PhD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Weighty Matters in HIV Treatment 2021 - Incorporating ARV Weight Gain into Clinical Decisions - François Venter

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - Clinical Case Presentation 2 - Focus on Women - Grace McComsey

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - Clinical Case Presentation 2 - Focus on Women - Grace McComsey

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - Clinical Case Presentation 1 - Focus on Young MSM - Jürgen Rockstroh

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - What are the Clinical Consequences of ARV Induced Weight Gain and Other Metabolic Toxicities? - John Robert Koethe

Weighty Matters in HIV Treatment 2021

Weighty Matters in HIV Treatment 2021 - ARV Associated Weight Gain: What are the Possible Mechanisms? - Laura Waters

Weighty Matters in HIV Treatment 2021

International Workshop on Monoclonal Antibodies fo-r HIV, COVID-19, and Oncology 2021 - Implementing Monoclonal Antibodies for Treatment and Prevention in Resource-Limited Settings - How to Make Them Affordable - David Ripin

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

How Will Technology Evolve: Modification of Antibodies - Boris Juelg, MD, PhD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

How to Determine the Dosing (in Different Populations/Tissues) - Edmund Capparelli, PharmD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in Hematologic Malignancies - Alison Moskowitz, MD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in Autoimmune Diseases - Karmela Kim Chan, MD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Prevention of HIV, COVID, and Ebola - Myron Cohen, MD, BS

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Monoclonal Antibodies for Treatment in COVID-19 - Florence Ader, Prof, MD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Clinical Case from the Region: Three Times “Loss of Consciousness” in an HIV Patient -- Hongxin Zhao

Chinese HIV Clinical Forum Educational Series 2021

Reduced Drug Regimens -- Linghua Li

Chinese HIV Clinical Forum Educational Series 2021

Monoclonal Antibodies Against COVID-19: Targets, Development and Clinical Applications - Brigette Autran, MD, PhD

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021 - Historical Perspectives from Pasteur to Flexner: The Evolution of Serum to Monoclonal Antibody Therapy- Charles W. Flexner

International Workshop on Monoclonal Antibodies for HIV, COVID-19, and Oncology 2021

Post-vaccination Infection with SARS-CoV-2 - Ravindra Gupta, MA, MPH, BMBCh, PhD, FRCP, FRCPath, FMedSci

COVID-19 Clinical Forum 2021

The Omicron Variant: Genetic Make-up and Spread - Penny Moore, PhD

COVID-19 Clinical Forum 2021